A detailed history of Ahl Investment Management, Inc. transactions in Abb Vie Inc. stock. As of the latest transaction made, Ahl Investment Management, Inc. holds 22,200 shares of ABBV stock, worth $3.9 Million. This represents 3.02% of its overall portfolio holdings.

Number of Shares
22,200
Previous 22,439 1.07%
Holding current value
$3.9 Million
Previous $3.85 Million 13.93%
% of portfolio
3.02%
Previous 2.82%

Shares

12 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Oct 30, 2024

SELL
$163.84 - $199.33 $39,157 - $47,639
-239 Reduced 1.07%
22,200 $4.38 Million
Q2 2024

Jul 15, 2024

BUY
$154.79 - $180.76 $154 - $180
1 Added 0.0%
22,439 $3.85 Million
Q1 2024

Apr 15, 2024

SELL
$159.82 - $182.1 $82,786 - $94,327
-518 Reduced 2.26%
22,438 $4.09 Million
Q4 2023

Jan 17, 2024

SELL
$137.6 - $154.97 $1,100 - $1,239
-8 Reduced 0.03%
22,956 $3.56 Million
Q3 2023

Oct 05, 2023

SELL
$133.59 - $154.65 $6,545 - $7,577
-49 Reduced 0.21%
22,964 $3.42 Million
Q2 2023

Jul 19, 2023

SELL
$132.51 - $164.9 $71,687 - $89,210
-541 Reduced 2.3%
23,013 $3.1 Million
Q1 2023

Apr 13, 2023

SELL
$144.61 - $166.54 $84,452 - $97,259
-584 Reduced 2.42%
23,554 $3.75 Million
Q4 2022

Jan 17, 2023

SELL
$138.31 - $165.87 $40,109 - $48,102
-290 Reduced 1.19%
24,138 $0
Q3 2022

Oct 14, 2022

SELL
$134.21 - $153.93 $4,563 - $5,233
-34 Reduced 0.14%
24,428 $3.28 Million
Q2 2022

Jul 20, 2022

SELL
$137.62 - $174.96 $429,649 - $546,225
-3,122 Reduced 11.32%
24,462 $3.75 Million
Q1 2022

Apr 28, 2022

SELL
$131.98 - $163.75 $114,030 - $141,480
-864 Reduced 3.04%
27,584 $4.47 Million
Q4 2021

Feb 03, 2022

BUY
$107.43 - $135.93 $3.06 Million - $3.87 Million
28,448 New
28,448 $3.85 Million

Others Institutions Holding ABBV

About AbbVie Inc.


  • Ticker ABBV
  • Exchange NYSE
  • Sector Healthcare
  • Industry Drug Manufacturers—General
  • Shares Outstandng 1,768,099,968
  • Market Cap $310B
  • Description
  • AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheuma...
More about ABBV
Track This Portfolio

Track Ahl Investment Management, Inc. Portfolio

Follow Ahl Investment Management, Inc. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Ahl Investment Management, Inc., based on Form 13F filings with the SEC.

News

Stay updated on Ahl Investment Management, Inc. with notifications on news.